menu
    • menu
    [{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"Radius Health","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Vosilasarm","moa":"Selective androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radius Health \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Radius Health \/ Ellipses Pharma"},{"orgOrder":0,"company":"Radius Health","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Radius Health \/ DRI Healthcare Trust","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by Radius Health

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Radius Health

                            U.S.A arrow
                            Legal Affairs
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            Legal Affairs
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : DRI Healthcare Trust

                            Deal Size : $140.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Radius Announces Royalty Purchase Agreement with DRI Healthcare to Sell a Portion of its Royalty and Commercia...

                            Details : Under the agreement, DRI Healthcare gains a portion of Radius’s royalty and commercial milestone stream in Orserdu (elacestrant), a selective estrogen receptor degrader and the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or ...

                            Product Name : RAD1901

                            Product Type : Other Small Molecule

                            Upfront Cash : $130.0 million

                            August 14, 2023

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : DRI Healthcare Trust

                            Deal Size : $140.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Radius Health

                            U.S.A arrow
                            Legal Affairs
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            Legal Affairs
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Menarini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

                            Details : RAD1901 (elacestrant) is the first and currently only investigational oral SERD to show positive topline results in a pivotal trial for the treatment of ER+/HER2- advanced or metastatic breast cancer in postmenopausal women, and men.

                            Product Name : RAD1901

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 22, 2022

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Menarini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Radius Health

                            U.S.A arrow
                            Legal Affairs
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            Legal Affairs
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Menarini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Radius Health & Menarini Group Provide Elacestrant Update

                            Details : Elacestrant is an oral Selective Estrogen Receptor Degrader (SERD) that is being studied in postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer.

                            Product Name : RAD1901

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 25, 2020

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Menarini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Radius Health

                            U.S.A arrow
                            Legal Affairs
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            Legal Affairs
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Menarini

                            Deal Size : $350.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization o...

                            Details : Elacestrant is an oral SERD, a selective estrogen receptor degrader, currently being evaluated in the EMERALD Phase 3 study as hormonal treatment for postmenopausal women and men with advanced ER+/HER2- breast cancer.

                            Product Name : RAD1901

                            Product Type : Other Small Molecule

                            Upfront Cash : $3.0 million

                            July 23, 2020

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Menarini

                            Deal Size : $350.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Radius Health

                            U.S.A arrow
                            Legal Affairs
                            Not Confirmed

                            Radius Health

                            U.S.A arrow
                            Legal Affairs
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Ellipses Pharma

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Radius Health Divests RAD 140 Program to Ellipses Pharma

                            Details : Under the agreement, Ellipses Pharma will be responsible for the clinical development and commercialization of RAD 140. Radius will be entitled to receive royalties on the program as it advances with Ellipses.

                            Product Name : RAD140

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 10, 2020

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Ellipses Pharma

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth